PT 141 Overview
The pt 141 peptide, also known as Bremelanotide, is a novel treatment for sexual dysfunction. It has been shown to improve hypoactive sexual desire disorder in women, and erectile dysfunction in men.
It activates the MC-4 receptor, which is known to influence sexual behavior and increase sexual arousal in both males and females[1]. The MC4 receptor also plays a key role in stimulating blood flow to the penis to generate an erection.
pt 141 is a synthetic, non-selective melanocortin agonist and has shown excellent oral and subcutaneous bioavailability in mice. It is currently being studied in a clinical trial for ED.
Doses: PT-141 is delivered through subcutaneous injections, which are administered 45 minutes before the intended sexual encounter. Alternatively, a nasal spray can be used in some cases.
How it Works:
PT 141 increases sexual desire and response by activating the central melanocortin receptors in the brain, which are involved in the sexual response. The MC4 receptor is also involved in controlling mood and emotion, which may contribute to arousal and desire.
Safety:
The PT 141 peptide is not without its risks, as it can cause flushing, nausea and vomiting in some patients. This can be caused by the medication itself, or by an allergic reaction to it.
How it Works:
PT 141 is an effective treatment for both hypoactive sexual desire disorder and erectile dysfunction, primarily due to its unique mechanism of action. It binds to the MC4 receptor, which has been proven to increase sexual arousal in both men and women, while inhibiting the nitrergic system that reduces blood flow to the genitals.